Prognostic factors identified in mucoepidermoid carcinoma

Prognostic factors identified in mucoepidermoid carcinoma
Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma of the salivary glands, while advanced disease stage and perineural invasion are the most significant indicators of poor prognosis, according to a study published in the Aug. 15 issue of Cancer.

(HealthDay) -- Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary glands, while advanced disease stage and perineural invasion are the most significant indicators of poor prognosis, according to a study published in the Aug. 15 issue of Cancer.

Catherine H. McHugh, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues retrospectively reviewed clinical data from 125 patients with MEC from 1990 to 2007.

The researchers found that, for all patients, the five-year overall survival was 79.3 percent and the disease-free survival was 76.5 percent. Low- and intermediate-grade disease correlated with significantly better overall and disease-free survival than high-grade disease, with no difference noted in between low- and intermediate-grade disease. Indicators of included pathologic results of positive lymph nodes, extracapsular lymph node spread, and perineural invasion. Advanced disease stage and perineural invasion were found to be the most significant on multivariate analysis.

"High histological grade, advanced stage, perineural invasion, positive surgical margins, and submandibular location all portend for unfavorable outcomes among patients with MEC," the authors write. "These factors should therefore be taken into consideration when establishing the aggressiveness of a treatment strategy."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Early response is an indicator for rectal cancer survival

Apr 10, 2012

(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

42 minutes ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

4 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

5 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.